Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06133647

Enrollment

Registered

2023-11-15

Start date

2023-05-04

Completion date

2025-05-01

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductal Carcinoma in Situ, Invasive Lobular Breast Carcinoma

Brief summary

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Detailed description

Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Interventions

PROCEDUREmanaging Male Breast Cancer Patients at Methodist Health System

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Inclusion criteria

* • ≥ 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast

Exclusion criteria

* 18 years of age * Prisoners * Pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Diagnosis Rates of patients with MBC and FBC	13 years	complications of treatment
Recurrence rates of Patients with MBC and FBC	13 years	Recurrence rates of Patients with MBC and FBC
Duration of remission in Patients with MBC and FBC	13 years	Duration of remission in Patients with MBC and FBC
The Overall Survival of patients with MBC and FBC after receiving treatment	13 years	The Overall Survival of patients with MBC and FBC after receiving treatment
Determine the complications of Treatment in patients with MBC and FBC	13 years	Determine the complications of Treatment in patients with MBC and FBC

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026